Without this pill, lots of people would be dead
Summary
This episode marks the 25th anniversary of Gleevec, a targeted therapy that revolutionized cancer care by turning chronic myeloid leukemia from fatal to survivable. Hosts Emily Kwong and Sydney Lufkin explore the drug’s origin, highlighting oncologist Brian Druker’s pioneering work and the collaborative effort between researchers, Novartis, and the FDA. The story features patient Mel Mann, who defied a three-year prognosis to live a full life, illustrating how Gleevec ushered in an era of personalized medicine.
Topics discussed
Intro: Tiny Desk Contest Tour and Shortwave welcome
Mel Mann's story: From terminal diagnosis to marathon runner
Sponsors: NetSuite and Edward Jones
The origin of Gleevec: Dr. Brian Druker's targeted therapy idea
Clinical trials: Unprecedented success and patient demand
Fast-track approval: Collaboration between NIH, FDA, and Novartis
Legacy of Gleevec: Targeted therapies and other cancers
Where are they now: Updates on Mel, Insa, and Dr. Druker
Outro: Credits and related episode recommendation
Trailers: Mint Mobile, Up First, and Fresh Air
Listen ad-free on Castria